Loading…

Tenascin Expression and Angiogenesis in Breast Cancers

The expression and the distribution of tenascin as well as the extent of blood vessel formation (angiogenesis) were investigated in 70 invasive human breast carcinomas. Formalin-fixed, paraffin-embedded specimens were stained with monoclonal antibody against tenascin-C (DAKO and Biogenex). Anti-CD31...

Full description

Saved in:
Bibliographic Details
Published in:Pathology, research and practice research and practice, 1999-01, Vol.195 (12), p.821-828
Main Authors: Tökés, Anna-Mária, Hortoványi, Eszter, Kulka, Janina, Jäkel, Márta, Kerényi, Tibor, Kádár, Anna
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c322t-e7ca205987c9970f1c0b77b3d702933c72dce22835730811dbbc5113adfa63f03
cites cdi_FETCH-LOGICAL-c322t-e7ca205987c9970f1c0b77b3d702933c72dce22835730811dbbc5113adfa63f03
container_end_page 828
container_issue 12
container_start_page 821
container_title Pathology, research and practice
container_volume 195
creator Tökés, Anna-Mária
Hortoványi, Eszter
Kulka, Janina
Jäkel, Márta
Kerényi, Tibor
Kádár, Anna
description The expression and the distribution of tenascin as well as the extent of blood vessel formation (angiogenesis) were investigated in 70 invasive human breast carcinomas. Formalin-fixed, paraffin-embedded specimens were stained with monoclonal antibody against tenascin-C (DAKO and Biogenex). Anti-CD31 antibody (Biogenex), an acknowledged marker of stromal angiogenesis, was used to detect endothelial cells. Tenascin immunostaining was positive in the tumours around the persisting normal ducts, around tumour-cell nests, in the neostroma, in some tumour cells, and it was found in or around vascular channels. Tumour vascularity was assessed by quantitative vascular grading (Chalkley point count) and was related to the localization and intensity of tenascin immunoreactivity. 19 tumours (27.1%) were scored as low, 35 (50%) as medium, and 16 (22.9%) as having a high vascular grade. The positive correlation between the vascular grade and the tenascin immunopositivity in tumour stroma was observed. Our results suggest that tenascin expression may be associated with endothelial cell activation and may play an important role in tumour angiogenesis.
doi_str_mv 10.1016/S0344-0338(99)80104-6
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_69403090</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0344033899801046</els_id><sourcerecordid>69403090</sourcerecordid><originalsourceid>FETCH-LOGICAL-c322t-e7ca205987c9970f1c0b77b3d702933c72dce22835730811dbbc5113adfa63f03</originalsourceid><addsrcrecordid>eNqFkD1PwzAQhi0EoqXwE0CZEAyBc5zY8YRKVT6kSgyU2XLsS2XUOsVuEfx7kqZCbEw33PPeq3sIOadwQ4Hy21dgeZ4CY-WVlNclUMhTfkCGlNMyBc7oIRn-IgNyEuM7AAjI6TEZ0A4QVAwJn6PX0TifTL_WAWN0jU-0t8nYL1yzQI_RxaRd3wfUcZNMtDcY4ik5qvUy4tl-jsjbw3Q-eUpnL4_Pk_EsNSzLNikKozMoZCmMlAJqaqASomJWQCYZMyKzBrOsZIVgUFJqq8oUlDJta81ZDWxELvu769B8bDFu1MpFg8ul9thso-IyBwayA4seNKGJMWCt1sGtdPhWFFQnTO2Eqc6GklLthCne5i72BdtqhfZPqjfUAnc9gO2bnw6Dam1hK8G6gGajbOP-qfgBWDx46Q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>69403090</pqid></control><display><type>article</type><title>Tenascin Expression and Angiogenesis in Breast Cancers</title><source>ScienceDirect Freedom Collection 2022-2024</source><creator>Tökés, Anna-Mária ; Hortoványi, Eszter ; Kulka, Janina ; Jäkel, Márta ; Kerényi, Tibor ; Kádár, Anna</creator><creatorcontrib>Tökés, Anna-Mária ; Hortoványi, Eszter ; Kulka, Janina ; Jäkel, Márta ; Kerényi, Tibor ; Kádár, Anna</creatorcontrib><description>The expression and the distribution of tenascin as well as the extent of blood vessel formation (angiogenesis) were investigated in 70 invasive human breast carcinomas. Formalin-fixed, paraffin-embedded specimens were stained with monoclonal antibody against tenascin-C (DAKO and Biogenex). Anti-CD31 antibody (Biogenex), an acknowledged marker of stromal angiogenesis, was used to detect endothelial cells. Tenascin immunostaining was positive in the tumours around the persisting normal ducts, around tumour-cell nests, in the neostroma, in some tumour cells, and it was found in or around vascular channels. Tumour vascularity was assessed by quantitative vascular grading (Chalkley point count) and was related to the localization and intensity of tenascin immunoreactivity. 19 tumours (27.1%) were scored as low, 35 (50%) as medium, and 16 (22.9%) as having a high vascular grade. The positive correlation between the vascular grade and the tenascin immunopositivity in tumour stroma was observed. Our results suggest that tenascin expression may be associated with endothelial cell activation and may play an important role in tumour angiogenesis.</description><identifier>ISSN: 0344-0338</identifier><identifier>EISSN: 1618-0631</identifier><identifier>DOI: 10.1016/S0344-0338(99)80104-6</identifier><identifier>PMID: 10631717</identifier><language>eng</language><publisher>Germany: Elsevier GmbH</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Angiogenesis ; Breast cancer ; Breast Neoplasms - blood supply ; Breast Neoplasms - metabolism ; Breast Neoplasms - pathology ; Carcinoma, Ductal, Breast - blood supply ; Carcinoma, Ductal, Breast - metabolism ; Carcinoma, Ductal, Breast - pathology ; Female ; Humans ; Immunoenzyme Techniques ; Ki-67 Antigen - metabolism ; Middle Aged ; Neoplasm Staging ; Neovascularization, Pathologic - metabolism ; Neovascularization, Pathologic - pathology ; Prognosis ; Receptors, Estrogen - metabolism ; Tenascin ; Tenascin - metabolism ; Tumor Suppressor Protein p53 - metabolism</subject><ispartof>Pathology, research and practice, 1999-01, Vol.195 (12), p.821-828</ispartof><rights>1999 Urban &amp; Fischer Verlag</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c322t-e7ca205987c9970f1c0b77b3d702933c72dce22835730811dbbc5113adfa63f03</citedby><cites>FETCH-LOGICAL-c322t-e7ca205987c9970f1c0b77b3d702933c72dce22835730811dbbc5113adfa63f03</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10631717$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tökés, Anna-Mária</creatorcontrib><creatorcontrib>Hortoványi, Eszter</creatorcontrib><creatorcontrib>Kulka, Janina</creatorcontrib><creatorcontrib>Jäkel, Márta</creatorcontrib><creatorcontrib>Kerényi, Tibor</creatorcontrib><creatorcontrib>Kádár, Anna</creatorcontrib><title>Tenascin Expression and Angiogenesis in Breast Cancers</title><title>Pathology, research and practice</title><addtitle>Pathol Res Pract</addtitle><description>The expression and the distribution of tenascin as well as the extent of blood vessel formation (angiogenesis) were investigated in 70 invasive human breast carcinomas. Formalin-fixed, paraffin-embedded specimens were stained with monoclonal antibody against tenascin-C (DAKO and Biogenex). Anti-CD31 antibody (Biogenex), an acknowledged marker of stromal angiogenesis, was used to detect endothelial cells. Tenascin immunostaining was positive in the tumours around the persisting normal ducts, around tumour-cell nests, in the neostroma, in some tumour cells, and it was found in or around vascular channels. Tumour vascularity was assessed by quantitative vascular grading (Chalkley point count) and was related to the localization and intensity of tenascin immunoreactivity. 19 tumours (27.1%) were scored as low, 35 (50%) as medium, and 16 (22.9%) as having a high vascular grade. The positive correlation between the vascular grade and the tenascin immunopositivity in tumour stroma was observed. Our results suggest that tenascin expression may be associated with endothelial cell activation and may play an important role in tumour angiogenesis.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Angiogenesis</subject><subject>Breast cancer</subject><subject>Breast Neoplasms - blood supply</subject><subject>Breast Neoplasms - metabolism</subject><subject>Breast Neoplasms - pathology</subject><subject>Carcinoma, Ductal, Breast - blood supply</subject><subject>Carcinoma, Ductal, Breast - metabolism</subject><subject>Carcinoma, Ductal, Breast - pathology</subject><subject>Female</subject><subject>Humans</subject><subject>Immunoenzyme Techniques</subject><subject>Ki-67 Antigen - metabolism</subject><subject>Middle Aged</subject><subject>Neoplasm Staging</subject><subject>Neovascularization, Pathologic - metabolism</subject><subject>Neovascularization, Pathologic - pathology</subject><subject>Prognosis</subject><subject>Receptors, Estrogen - metabolism</subject><subject>Tenascin</subject><subject>Tenascin - metabolism</subject><subject>Tumor Suppressor Protein p53 - metabolism</subject><issn>0344-0338</issn><issn>1618-0631</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1999</creationdate><recordtype>article</recordtype><recordid>eNqFkD1PwzAQhi0EoqXwE0CZEAyBc5zY8YRKVT6kSgyU2XLsS2XUOsVuEfx7kqZCbEw33PPeq3sIOadwQ4Hy21dgeZ4CY-WVlNclUMhTfkCGlNMyBc7oIRn-IgNyEuM7AAjI6TEZ0A4QVAwJn6PX0TifTL_WAWN0jU-0t8nYL1yzQI_RxaRd3wfUcZNMtDcY4ik5qvUy4tl-jsjbw3Q-eUpnL4_Pk_EsNSzLNikKozMoZCmMlAJqaqASomJWQCYZMyKzBrOsZIVgUFJqq8oUlDJta81ZDWxELvu769B8bDFu1MpFg8ul9thso-IyBwayA4seNKGJMWCt1sGtdPhWFFQnTO2Eqc6GklLthCne5i72BdtqhfZPqjfUAnc9gO2bnw6Dam1hK8G6gGajbOP-qfgBWDx46Q</recordid><startdate>19990101</startdate><enddate>19990101</enddate><creator>Tökés, Anna-Mária</creator><creator>Hortoványi, Eszter</creator><creator>Kulka, Janina</creator><creator>Jäkel, Márta</creator><creator>Kerényi, Tibor</creator><creator>Kádár, Anna</creator><general>Elsevier GmbH</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19990101</creationdate><title>Tenascin Expression and Angiogenesis in Breast Cancers</title><author>Tökés, Anna-Mária ; Hortoványi, Eszter ; Kulka, Janina ; Jäkel, Márta ; Kerényi, Tibor ; Kádár, Anna</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c322t-e7ca205987c9970f1c0b77b3d702933c72dce22835730811dbbc5113adfa63f03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1999</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Angiogenesis</topic><topic>Breast cancer</topic><topic>Breast Neoplasms - blood supply</topic><topic>Breast Neoplasms - metabolism</topic><topic>Breast Neoplasms - pathology</topic><topic>Carcinoma, Ductal, Breast - blood supply</topic><topic>Carcinoma, Ductal, Breast - metabolism</topic><topic>Carcinoma, Ductal, Breast - pathology</topic><topic>Female</topic><topic>Humans</topic><topic>Immunoenzyme Techniques</topic><topic>Ki-67 Antigen - metabolism</topic><topic>Middle Aged</topic><topic>Neoplasm Staging</topic><topic>Neovascularization, Pathologic - metabolism</topic><topic>Neovascularization, Pathologic - pathology</topic><topic>Prognosis</topic><topic>Receptors, Estrogen - metabolism</topic><topic>Tenascin</topic><topic>Tenascin - metabolism</topic><topic>Tumor Suppressor Protein p53 - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tökés, Anna-Mária</creatorcontrib><creatorcontrib>Hortoványi, Eszter</creatorcontrib><creatorcontrib>Kulka, Janina</creatorcontrib><creatorcontrib>Jäkel, Márta</creatorcontrib><creatorcontrib>Kerényi, Tibor</creatorcontrib><creatorcontrib>Kádár, Anna</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Pathology, research and practice</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tökés, Anna-Mária</au><au>Hortoványi, Eszter</au><au>Kulka, Janina</au><au>Jäkel, Márta</au><au>Kerényi, Tibor</au><au>Kádár, Anna</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Tenascin Expression and Angiogenesis in Breast Cancers</atitle><jtitle>Pathology, research and practice</jtitle><addtitle>Pathol Res Pract</addtitle><date>1999-01-01</date><risdate>1999</risdate><volume>195</volume><issue>12</issue><spage>821</spage><epage>828</epage><pages>821-828</pages><issn>0344-0338</issn><eissn>1618-0631</eissn><abstract>The expression and the distribution of tenascin as well as the extent of blood vessel formation (angiogenesis) were investigated in 70 invasive human breast carcinomas. Formalin-fixed, paraffin-embedded specimens were stained with monoclonal antibody against tenascin-C (DAKO and Biogenex). Anti-CD31 antibody (Biogenex), an acknowledged marker of stromal angiogenesis, was used to detect endothelial cells. Tenascin immunostaining was positive in the tumours around the persisting normal ducts, around tumour-cell nests, in the neostroma, in some tumour cells, and it was found in or around vascular channels. Tumour vascularity was assessed by quantitative vascular grading (Chalkley point count) and was related to the localization and intensity of tenascin immunoreactivity. 19 tumours (27.1%) were scored as low, 35 (50%) as medium, and 16 (22.9%) as having a high vascular grade. The positive correlation between the vascular grade and the tenascin immunopositivity in tumour stroma was observed. Our results suggest that tenascin expression may be associated with endothelial cell activation and may play an important role in tumour angiogenesis.</abstract><cop>Germany</cop><pub>Elsevier GmbH</pub><pmid>10631717</pmid><doi>10.1016/S0344-0338(99)80104-6</doi><tpages>8</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0344-0338
ispartof Pathology, research and practice, 1999-01, Vol.195 (12), p.821-828
issn 0344-0338
1618-0631
language eng
recordid cdi_proquest_miscellaneous_69403090
source ScienceDirect Freedom Collection 2022-2024
subjects Adult
Aged
Aged, 80 and over
Angiogenesis
Breast cancer
Breast Neoplasms - blood supply
Breast Neoplasms - metabolism
Breast Neoplasms - pathology
Carcinoma, Ductal, Breast - blood supply
Carcinoma, Ductal, Breast - metabolism
Carcinoma, Ductal, Breast - pathology
Female
Humans
Immunoenzyme Techniques
Ki-67 Antigen - metabolism
Middle Aged
Neoplasm Staging
Neovascularization, Pathologic - metabolism
Neovascularization, Pathologic - pathology
Prognosis
Receptors, Estrogen - metabolism
Tenascin
Tenascin - metabolism
Tumor Suppressor Protein p53 - metabolism
title Tenascin Expression and Angiogenesis in Breast Cancers
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T21%3A38%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Tenascin%20Expression%20and%20Angiogenesis%20in%20Breast%20Cancers&rft.jtitle=Pathology,%20research%20and%20practice&rft.au=T%C3%B6k%C3%A9s,%20Anna-M%C3%A1ria&rft.date=1999-01-01&rft.volume=195&rft.issue=12&rft.spage=821&rft.epage=828&rft.pages=821-828&rft.issn=0344-0338&rft.eissn=1618-0631&rft_id=info:doi/10.1016/S0344-0338(99)80104-6&rft_dat=%3Cproquest_cross%3E69403090%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c322t-e7ca205987c9970f1c0b77b3d702933c72dce22835730811dbbc5113adfa63f03%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=69403090&rft_id=info:pmid/10631717&rfr_iscdi=true